CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle

Zhou,Hao-Yu; Wang,Yi-Chang; Wang,Tuo; Wu,Wei; Cao,Yi-Yang; Zhang,Bei-Chen; Wang,Mao-De; Mao,Ping

doi:10.3892/ol.2024.14339

CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle

Authors:
- Hao-Yu Zhou
- Yi-Chang Wang
- Tuo Wang
- Wei Wu
- Yi-Yang Cao
- Bei-Chen Zhang
- Mao-De Wang
- Ping Mao
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: March 13, 2024 https://doi.org/10.3892/ol.2024.14339
Article Number: 206
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is characterized by significant heterogeneity, leading to poor survival outcomes for patients, despite the implementation of comprehensive treatment strategies. The roles of cyclin A2 (CCNA2) and NIMA related kinase 2 (NEK2) have been extensively studied in numerous cancers, but their specific functions in GBM remain to be elucidated. The present study aimed to investigate the potential molecular mechanisms of CCNA2 and NEK2 in GBM. CCNA2 and NEK2 expression and prognosis in glioma were evaluated by bioinformatics methods. In addition, the distribution of CCNA2 and NEK2 expression in GBM subsets was determined using pseudo‑time analysis and tricycle position of single‑cell sequencing. Gene Expression Omnibus and Kyoto Encyclopedia of Genes and Genome databases were employed and enrichment analyses were conducted to investigate potential signaling pathways in GBM subsets and a nomogram was established to predict 1‑, 2‑ and 3‑year overall survival probability in GBM. CCNA2 and NEK2 expression levels were further validated by western blot analysis and immunohistochemical staining in GBM samples. High expression of CCNA2 and NEK2 in glioma indicates poor clinical outcomes. Single‑cell sequencing of GBM revealed that these genes were upregulated in a subset of positive neural progenitor cells (P‑NPCs), which showed significant proliferation and progression properties and may activate G2M checkpoint pathways. A comprehensive nomogram predicts 1‑, 2‑ and 3‑year overall survival probability in GBM by considering P‑NPCs, age, chemotherapy and radiotherapy scores. CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle, thus indicating the potential of novel therapy directed to CCNA2 and NEK2 in GBM.

View Figures

View References

1	Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 24 (Suppl 5):v1–v95. 2022. View Article : Google Scholar : PubMed/NCBI
2	Xu S, Tang L, Li X, Fan F and Liu Z: Immunotherapy for glioma: Current management and future application. Cancer Lett. 476:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
3	Liu Y, Lang F and Yang C: NRF2 in human neoplasm: Cancer biology and potential therapeutic target. Pharmacol Ther. 217:1076642021. View Article : Google Scholar : PubMed/NCBI
4	Asad AS, Candia AJN, González N, Zuccato CF, Seilicovich A and Candolfi M: Current non-viral gene therapy strategies for the treatment of glioblastoma. Curr Med Chem. 28:7729–7748. 2021. View Article : Google Scholar : PubMed/NCBI
5	Shergalis A, Bankhead A III, Luesakul U, Muangsin N and Neamati N: Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 70:412–445. 2018. View Article : Google Scholar : PubMed/NCBI
6	Huang PH, Xu AM and White FM: Oncogenic EGFR signaling networks in glioma. Sci Signal. 2:re62009. View Article : Google Scholar : PubMed/NCBI
7	Liu H, Liu B, Hou X, Pang B, Guo P, Jiang W, Ding Q, Zhang R, Xin T, Guo H, et al: Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma. J Neurooncol. 132:409–417. 2017. View Article : Google Scholar : PubMed/NCBI
8	Xiang J, Alafate W, Wu W, Wang Y, Li X, Xie W, Bai X, Li R, Wang M and Wang J: NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway. Cell Death Dis. 13:582022. View Article : Google Scholar : PubMed/NCBI
9	Xia J, Franqui Machin R, Gu Z and Zhan F: Role of NEK2A in human cancer and its therapeutic potentials. Biomed Res Int. 2015:8624612015. View Article : Google Scholar : PubMed/NCBI
10	Faragher AJ and Fry AM: Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 14:2876–2889. 2003. View Article : Google Scholar : PubMed/NCBI
11	Jeong Y, Lee J, Kim K, Yoo JC and Rhee K: Characterization of NIP2/centrobin, a novel substrate of Nek2, and its potential role in microtubule stabilization. J Cell Sci. 120:2106–2116. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zhong X, Guan X, Liu W and Zhang L: Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer. Oncol Lett. 8:1470–1476. 2014. View Article : Google Scholar : PubMed/NCBI
13	Gu Z, Xia J, Xu H, Frech I, Tricot G and Zhan F: NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase. J Hematol Oncol. 10:172017. View Article : Google Scholar : PubMed/NCBI
14	Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, et al: NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 12:45362021. View Article : Google Scholar : PubMed/NCBI
15	Lee J and Gollahon L: Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells. Cell Cycle. 12:3599–3614. 2013. View Article : Google Scholar : PubMed/NCBI
16	Fang Y and Zhang X: Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle. 15:895–907. 2016. View Article : Google Scholar : PubMed/NCBI
17	Qi C, Lei L, Hu J, Wang G, Liu J and Ou S: Serine incorporator 2 (SERINC2) expression predicts an unfavorable prognosis of low-grade glioma (LGG): Evidence from bioinformatics analysis. J Mol Neurosci. 70:1521–1532. 2020. View Article : Google Scholar : PubMed/NCBI
18	Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J. 11:961–971. 1992. View Article : Google Scholar : PubMed/NCBI
19	Murphy M, Stinnakre MG, Senamaud-Beaufort C, Winston NJ, Sweeney C, Kubelka M, Carrington M, Bréchot C and Sobczak-Thépot J: Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet. 15:83–86. 1997. View Article : Google Scholar : PubMed/NCBI
20	Jiang A, Zhou Y, Gong W, Pan X, Gan X, Wu Z, Liu B, Qu L and Wang L: CCNA2 as an immunological biomarker encompassing tumor microenvironment and therapeutic response in multiple cancer types. Oxid Med Cell Longev. 2022:59105752022. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Zhong Q, Li Z, Lin Z, Chen H and Wang P: Integrated profiling identifies CCNA2 as a potential biomarker of immunotherapy in breast cancer. Onco Targets Ther. 14:2433–2448. 2021. View Article : Google Scholar : PubMed/NCBI
22	Li Z, Zhang Y, Zhou Y, Wang F, Yin C, Ding L and Zhang S: Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway. Sci Rep. 11:236812021. View Article : Google Scholar : PubMed/NCBI
23	Gan Y, Li Y, Li T, Shu G and Yin G: CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res. 10:5113–5124. 2018. View Article : Google Scholar : PubMed/NCBI
24	Cai Y and Yang W: PKMYT1 regulates the proliferation and epithelial-mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2. Oncol Lett. 23:632022. View Article : Google Scholar : PubMed/NCBI
25	Bendris N, Arsic N, Lemmers B and Blanchard JM: Cyclin A2, Rho GTPases and EMT. Small GTPases. 3:225–228. 2012. View Article : Google Scholar : PubMed/NCBI
26	Li J, Ying Y, Xie H, Jin K, Yan H, Wang S, Xu M, Xu X, Wang X, Yang K, et al: Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. FASEB J. 33:1374–1388. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhang J, Liu X, Zhou W, Lu S, Wu C, Wu Z, Liu R, Li X, Wu J, Liu Y, et al: Identification of key genes associated with the process of hepatitis B inflammation and cancer transformation by integrated bioinformatics analysis. Front Genet. 12:6545172021. View Article : Google Scholar : PubMed/NCBI
28	Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M, Liu J and Zhao Q: Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 14:124–136. 2018. View Article : Google Scholar : PubMed/NCBI
29	Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, et al: Chinese glioma genome atlas (CGGA): A comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteomics Bioinformatics. 19:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
30	Cancer Genome Atlas Research Network, . Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet. 45:1113–130. 2013. View Article : Google Scholar : PubMed/NCBI
31	Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, et al: An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 178:835–849.e21. 2019. View Article : Google Scholar : PubMed/NCBI
32	Satija R, Farrell JA, Gennert D, Schier AF and Regev A: Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 33:495–502. 2015. View Article : Google Scholar : PubMed/NCBI
33	Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR, et al: Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 20:163–172. 2019. View Article : Google Scholar : PubMed/NCBI
34	Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, Chen J, Jiang W, Yang K, Ou Q, et al: CellMarker 2.0: An updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 51(D1): D870–D876. 2023. View Article : Google Scholar : PubMed/NCBI
35	Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, Luo HY, Zeng ZL, Qiu MZ and Xu RH: Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 14:452022. View Article : Google Scholar : PubMed/NCBI
36	Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, Lennon NJ, Livak KJ, Mikkelsen TS and Rinn JL: The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 32:381–386. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zheng SC, Stein-O'Brien G, Augustin JJ, Slosberg J, Carosso GA, Winer B, Shin G, Bjornsson HT, Goff LA and Hansen KD: Universal prediction of cell-cycle position using transfer learning. Genome Biol. 23:412022. View Article : Google Scholar : PubMed/NCBI
38	Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP and Tamayo P: The Molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
39	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
40	Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344:1396–1401. 2014. View Article : Google Scholar : PubMed/NCBI
41	Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, et al: Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 10:116–125. 2009. View Article : Google Scholar : PubMed/NCBI
42	Kinoshita M, Uchida T, Sato A, Nakashima M, Nakashima H, Shono S, Habu Y, Miyazaki H, Hiroi S and Seki S: Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice. J Hepatol. 53:903–910. 2010. View Article : Google Scholar : PubMed/NCBI
43	Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A, et al: Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 181:442–459.e29. 2020. View Article : Google Scholar : PubMed/NCBI
44	Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, et al: A single-cell survey of the small intestinal epithelium. Nature. 551:333–339. 2017. View Article : Google Scholar : PubMed/NCBI
45	Qiu J, Qu X, Wang Y, Guo C, Lv B, Jiang Q, Su W, Wang L and Hua K: Single-cell landscape highlights heterogenous microenvironment, novel immune reaction patterns, potential biomarkers and unique therapeutic strategies of cervical squamous carcinoma, human papillomavirus-associated (HPVA) and non-HPVA adenocarcinoma. Adv Sci (Weinh). 10:e22049512023. View Article : Google Scholar : PubMed/NCBI
46	van der Poel M, Ulas T, Mizee MR, Hsiao CC, Miedema SSM, Adelia Schuurman KG, Helder B, Tas SW, Schultze JL, et al: Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes. Nat Commun. 10:11392019. View Article : Google Scholar : PubMed/NCBI
47	Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, Boeckx B, Vanden Bempt M, Nevelsteen I, Lambein K, et al: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 27:820–832. 2021. View Article : Google Scholar : PubMed/NCBI
48	Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, et al: SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 184:6243–6261.e27. 2021. View Article : Google Scholar : PubMed/NCBI
49	Gong Z, Li Q, Shi J, Li P, Hua L, Shultz LD and Ren G: Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis. Sci Immunol. 8:eadd52042023. View Article : Google Scholar : PubMed/NCBI
50	Kennedy A, Waters E, Rowshanravan B, Hinze C, Williams C, Janman D, Fox TA, Booth C, Pesenacker AM, Halliday N, et al: Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nat Immunol. 23:1365–1378. 2022. View Article : Google Scholar : PubMed/NCBI
51	Amiry-Moghaddam M: AQP4 and the fate of gliomas. Cancer Res. 79:2810–2811. 2019. View Article : Google Scholar : PubMed/NCBI
52	Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, et al: Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 175:1665–1678.e18. 2018. View Article : Google Scholar : PubMed/NCBI
53	Kakogiannos N, Ferrari L, Giampietro C, Scalise AA, Maderna C, Ravà M, Taddei A, Lampugnani MG, Pisati F, Malinverno M, et al: JAM-A acts via C/EBP-α to promote claudin-5 expression and enhance endothelial barrier function. Circ Res. 127:1056–1073. 2020. View Article : Google Scholar : PubMed/NCBI
54	Hosmann A, Jaber M, Roetzer-Pejrimovsky T, Timelthaler G, Borkovec M, Kiesel B, Wadiura LI, Millesi M, Mercea PA, Phillips J, et al: CD34 microvascularity in low-grade glioma: Correlation with 5-aminolevulinic acid fluorescence and patient prognosis in a multicenter study at three specialized centers. J Neurosurg. 138:1281–1290. 20232PubMed/NCBI
55	Agostini M, Amato F, Vieri ML, Greco G, Tonazzini I, Baroncelli L, Caleo M, Vannini E, Santi M, Signore G and Cecchini M: Glial-fibrillary-acidic-protein (GFAP) biomarker detection in serum-matrix: Functionalization strategies and detection by an ultra-high-frequency surface-acoustic-wave (UHF-SAW) lab-on-chip. Biosens Bioelectron. 172:1127742021. View Article : Google Scholar : PubMed/NCBI
56	Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, Lan X, Zhang L, Miao JY, Wang YX, et al: EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther. 7:332022. View Article : Google Scholar : PubMed/NCBI
57	Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, et al: Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 157:580–594. 2014. View Article : Google Scholar : PubMed/NCBI
58	Yang Y, Chu L, Zeng Z, Xu S, Yang H, Zhang X, Jia J, Long N, Hu Y and Liu J: Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis. Bioengineered. 12:6643–6654. 2021. View Article : Google Scholar : PubMed/NCBI
59	Bendris N, Loukil A, Cheung C, Arsic N, Rebouissou C, Hipskind R, Peter M, Lemmers B and Blanchard JM: Cyclin A2: A genuine cell cycle regulator? Biomol Concepts. 3:535–543. 2012. View Article : Google Scholar : PubMed/NCBI
60	Loukil A, Cheung CT, Bendris N, Lemmers B, Peter M and Blanchard JM: Cyclin A2: At the crossroads of cell cycle and cell invasion. World J Biol Chem. 6:346–350. 2015. View Article : Google Scholar : PubMed/NCBI
61	Liang W, Guan H, He X, Ke W, Xu L, Liu L, Xiao H and Li Y: Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget. 6:31780–31791. 2015. View Article : Google Scholar : PubMed/NCBI
62	Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA and Mann M: Proteomic characterization of the human centrosome by protein correlation profiling. Nature. 426:570–574. 2003. View Article : Google Scholar : PubMed/NCBI
63	O'regan L, Blot J and Fry AM: Mitotic regulation by NIMA-related kinases. Cell Div. 2:252007. View Article : Google Scholar : PubMed/NCBI
64	Huang X, Zhang G, Tang T, Gao X and Liang T: One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment. Biochim Biophys Acta Rev Cancer. 1877:1886962022. View Article : Google Scholar : PubMed/NCBI
65	Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A and Parada LF: Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 15:45–56. 2009. View Article : Google Scholar : PubMed/NCBI
66	Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L and Zong H: Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell. 146:209–221. 2011. View Article : Google Scholar : PubMed/NCBI
67	Hydbring P, Malumbres M and Sicinski P: Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016. View Article : Google Scholar : PubMed/NCBI
68	Huang J, Li Q, Peng Q, Xie Y, Wang W, Pei C, Zhao Y, Liu R, Huang L, Li T, et al: Single-cell RNA sequencing reveals heterogeneity and differential expression of decidual tissues during the peripartum period. Cell Prolif. 54:e129672021. View Article : Google Scholar : PubMed/NCBI
69	Zhao T, Fu Y, Zhu J, Liu Y, Zhang Q, Yi Z, Chen S, Jiao Z, Xu X, Xu J, et al: Single-cell RNA-Seq reveals dynamic early embryonic-like programs during chemical reprogramming. Cell Stem Cell. 23:31–45.e7. 2018. View Article : Google Scholar : PubMed/NCBI
70	Balducci M, Chiesa S, Diletto B, D'Agostino GR, Mangiola A, Manfrida S, Mantini G, Albanese A, Fiorentino A, Frascino V, et al: Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: A feasibility study. Neuro Oncol. 14:79–86. 2012. View Article : Google Scholar : PubMed/NCBI
71	Kong L, Gao J, Hu J, Lu R, Yang J, Qiu X, Hu W and Lu JJ: Carbon ion radiotherapy boost in the treatment of glioblastoma: A randomized phase I/III clinical trial. Cancer Commun (Lond). 39:52019.PubMed/NCBI
72	Kops GJ, Weaver BA and Cleveland DW: On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 5:773–785. 2005. View Article : Google Scholar : PubMed/NCBI
73	Nicholson JM and Cimini D: How mitotic errors contribute to karyotypic diversity in cancer. Adv Cancer Res. 112:43–75. 2011. View Article : Google Scholar : PubMed/NCBI
74	Fry AM, O'Regan L, Sabir SR and Bayliss R: Cell cycle regulation by the NEK family of protein kinases. J Cell Sci. 125:4423–4433. 2012.PubMed/NCBI
75	Fry AM, Meraldi P and Nigg EA: A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 17:470–481. 1998. View Article : Google Scholar : PubMed/NCBI
76	Li JJ and Li SA: Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther. 111:974–984. 2006. View Article : Google Scholar : PubMed/NCBI
77	Helps NR, Luo X, Barker HM and Cohen PT: NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1. Biochem J. 349:509–518. 2000. View Article : Google Scholar : PubMed/NCBI
78	Chotiner JY, Wolgemuth DJ and Wang PJ: Functions of cyclins and CDKs in mammalian gametogenesis†. Biol Reprod. 101:591–601. 2019. View Article : Google Scholar : PubMed/NCBI
79	Jiang F, Luo F, Zeng N, Mao Y, Tang X, Wang J, Hu Y and Wu C: Characterization of fatty acid metabolism-related genes landscape for predicting prognosis and aiding immunotherapy in glioma patients. Front Immunol. 13:9021432022. View Article : Google Scholar : PubMed/NCBI
80	Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, et al: The epidemiology of glioma in adults: A ‘state of the science’ review. Neuro Oncol. 16:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
81	Sturm D, Pfister SM and Jones DTW: Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 35:2370–2377. 2017. View Article : Google Scholar : PubMed/NCBI
82	Ashby LS and Ryken TC: Management of malignant glioma: Steady progress with multimodal approaches. Neurosurg Focus. 20:E32006. View Article : Google Scholar : PubMed/NCBI
83	Andersen BM, Faust Akl C, Wheeler MA, Chiocca EA, Reardon DA and Quintana FJ: Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat Rev Cancer. 21:786–802. 2021. View Article : Google Scholar : PubMed/NCBI
84	Martínez-Cerdeño V and Noctor SC: Neural progenitor cell terminology. Front Neuroanat. 12:1042018. View Article : Google Scholar : PubMed/NCBI
85	Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A and Parada LF: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 8:119–130. 2005. View Article : Google Scholar : PubMed/NCBI
86	Zarco N, Norton E, Quiñones-Hinojosa A and Guerrero-Cázares H: Overlapping migratory mechanisms between neural progenitor cells and brain tumor stem cells. Cell Mol Life Sci. 76:3553–3570. 2019. View Article : Google Scholar : PubMed/NCBI
87	Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al: p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 455:1129–1133. 2008. View Article : Google Scholar : PubMed/NCBI
88	Jung E, Alfonso J, Osswald M, Monyer H, Wick W and Winkler F: Emerging intersections between neuroscience and glioma biology. Nat Neurosci. 22:1951–1960. 2019. View Article : Google Scholar : PubMed/NCBI
89	Schonberg DL, Lubelski D, Miller TE and Rich JN: Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 39:82–101. 2014. View Article : Google Scholar : PubMed/NCBI
90	Kohwi M and Doe CQ: Temporal fate specification and neural progenitor competence during development. Nat Rev Neurosci. 14:823–838. 2013. View Article : Google Scholar : PubMed/NCBI
91	Yabo YA, Niclou SP and Golebiewska A: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol. 24:669–682. 2022. View Article : Google Scholar : PubMed/NCBI
92	Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
93	Liu L, Michowski W, Kolodziejczyk A and Sicinski P: The cell cycle in stem cell proliferation, pluripotency and differentiation. Nat Cell Biol. 21:1060–1067. 2019. View Article : Google Scholar : PubMed/NCBI
94	Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature. 501:328–337. 2013. View Article : Google Scholar : PubMed/NCBI
95	Roninson IB, Broude EV and Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 4:303–313. 2001. View Article : Google Scholar : PubMed/NCBI
96	Castro-Gamero AM, Pezuk JA, Brassesco MS and Tone LG: G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: The old, the new, and the future. Cancer Biol Med. 15:354–374. 2018. View Article : Google Scholar : PubMed/NCBI